Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2009-05-28
2011-12-06
Minnifield, Nita M (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
Reexamination Certificate
active
08071084
ABSTRACT:
Compositions and methods for protecting a susceptible host against an infection ofShigella sonneiare disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.
REFERENCES:
patent: 4632830 (1986-12-01), Formal et al.
patent: 5672345 (1997-09-01), Curtiss, III
patent: 5980907 (1999-11-01), Dougan et al.
patent: 6190669 (2001-02-01), Noriega et al.
Bélanger, Myriam et al., “Functional analysis of genes responsible for the synthesis of the B-band O antigen ofPseudomonas aeruginosaserotype O6 lipopolysaccharide,” Microbiology, 1999, vol. 145, pp. 3505-3521.
Bilge, Sima S. et al., “Role of theEscherichia coliO157:H7 O Side Chain in Adherence and Analysis of anrfbLocus,” Infection and Immunity, 1996, vol. 64, pp. 4795-4801.
Black, Robert E. et al., “Prevention of Shigellosis by aSalmonella typhi-Shigella sonneiBivalent Vaccine,” The Journal of Infectious Diseases, 1987, vol. 155, pp. 1260-1265.
Bowie, James U. et al., “Deciphering the Message in Protein Sequences: Tolerance to amino Acid Substitutions,” Science, 1990, vol. 247, pp. 1306-1310.
Burgess, Wilson H. et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” The Journal of Cell Biology, 1990, vol. 111, pp. 2129-2138.
Burrows, Lori L. et al., “Functional Conservation of the Polysaccharide Biosynthetic Protein WbpM and Its Homologues inPseudomonas aeruginosaand Other Medically Significant Bacteria,” Infection and Immunity, 2000, vol. 68, pp. 931-936.
Chida, Toshio et al., “The Complete DNA Sequence of the O Antigen Gene Region ofPlesiomonas shigelloidesSerotype O17 Which Is Identical toShigella sonneiForm 1 Antigen,” Microbiology and Immunology, 2000, vol. 44, pp. 161-172.
Creuzenet, Carole et al., “FlaA1, a New Bifunctional UDP-GlcNAc C6Dehydratase/C4Reductase fromHelicobacter pylori,” The Journal of Biological Chemistry, 2000, vol. 275, pp. 34873-34880.
DuPont, Herbert et al., “Immunity in Shigellosis. I. Response of Man to Attenuated Strains ofShigella,” The Journal of Infectious Diseases, 1972, vol. 125, pp. 5-11.
Ertesvåg, Helga et al., “Cloning and Expression of anAzotobacter vinelandiiMannuronan C-5-Epimerase Gene,” Journal of Bacteriology, 1994, vol. 176, pp. 2846-2853.
Formal, B. et al., “Construction of a Potential Bivalent Vaccine Strain: Introduction ofShigella sonneiForm I Antigen Genes into thegalE Salmonella typhiTy21a Typhoid Vaccine Strain,” Infection and Immunity, 1981, vol. 34, pp. 746-750.
Franklin, Michael J. et al., “Pseudomonas aeruginosaAlgG Is a Polymer Level Alginate C5-Mannuronan Epimerase,” Journal of Bacteriology, 1994, vol. 176, pp. 1821-1830.
Galán, Jorge E. et al., “Cloning and characterization of theasdgene ofSalmonella typhimurium: use in stable maintenance of recombinant plasmids inSalmonellavaccine strains,” Gene, 1990, vol. 94, pp. 29-35.
Germanier, R. and Fürer, E., “Isolation and Characterization ofGalE Mutant Ty 21a ofSalmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine,” The Journal of Infectious Diseases, 1975, vol. 131, pp. 553-558.
Gotschlich, Emil C., “Genetic Locus for the Biosynthesis of the Variable Portion ofNeisseria gonorrhoeaeLipooligosaccharide,” The Journal of Experimental Medicine, 1994, vol. 180, pp. 2181-2190.
Hartman, Antoinette B. and Venkatesan, Malabi M., “Construction of a Stable AttenuatedShigella sonnei ΔvirGVaccine Strain, WRSS1, and Protective Efficacy and Immunogenicity in the Guinea Pig Keratoconjunctivitis Model,” Infection and Immunity, 1998, vol. 66, pp. 4572-4576.
Hartman, Antoinette B. et al., “Molecular Analysis of Variant Plasmid Forms of a BivalentSalmonella typhi-Shigella sonneiVaccine Strain,” Journal of Clinical Microbiology, 1991, vol. 29, pp. 27-32.
Hashimoto, Yasuhiro et al., “Complete Nucleotide Sequence and Molecular Characterization of ViaB Region Encoding Vi Antigen inSalmonella typhi,” Journal of Bacteriology, 1993, vol. 175, pp. 4456-4465.
Heinrichs, David E. et al., “The Assembly System for the Lipopolysaccharide R2 Core-type ofEscherichia coliIs a Hybrid of Those Found inEscherichia coliK-12 andSalmonella enterica,” The Journal of Biological Chemistry, 1998, vol. 273, pp. 8849-8859.
Herrington, Deirdre A. et al., “Studies in volunteers to evaluate candidateShigellavaccines: further experience with a bivalentSalmonella typhi-Shigella sonneivaccine and protection conferred by previousShigella sonneiDisease,” Vaccine, 1990, vol. 8, pp. 353-357.
Kenne, Lennart et al., “Structural Studies of the O-Specific Side-chains of theShigella sonneiPhase I Lipopolysaccharide,” 1980, vol. 78, pp. 119-126.
Keren, David F. et al., “Intestinal Immunoglobulin A Responses in Rabbits to aSalmonella typhiStrain Harboring aShigella sonneiPlasmid,” Infection and Immunity, 1982, vol. 37, pp. 387-389.
Kopecko, Dennis J. et al., “Genetic and Physical Evidence for Plasmid Control ofShigella sonneiForm I Cell Surface Antigen,” Infection and Immunity, 1980, vol. 29, pp. 207-214.
Lazar Eliane et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 1988, vol. 8, pp. 1247-1252.
Li, Jin-ping et al., “Biosynthesis of Heparin/Heparan Sulfate: cDNA cloning and expression ofD-glucuronyl C5-Epimerase from Bovine Lung,” The Journal of Biological Chemistry, 1997, vol. 272, pp. 28158-28163.
Paulsen, Ian T. et al., “A family of Gram-negative bacterial outer membrane factors that function in the export of proteins, carbohydrates, drugs and heavy metals from Gram-negative bacteria,” FEMS Microbiology Letters, 1997, vol. 156, pp. 1-8.
Sansonetti, Philippe J. et al., “Shigella sonneiPlasmids: Evidence that a Large Plasmid is Necessary for Virulence,” Infection and Immunity, 1981, vol. 34, pp. 75-83.
Seid Jr., Robert C. et al., “Unusual Lipopolysaccharide Antigens of aSalmonella typhiOral Vaccine Strain Expressing theShigella sonneiFrom I Antigen,” The Journal of Biological Chemistry, 1984, vol. 259, pp. 9028-9034.
Shepherd, James G. et al., “Comparison of O-Antigen Gene Clusters ofEscherichia coli(Shigella)sonneiandPlesiomonas shigelloidesO17:SonneiGained its Current Plasmid-Borne O-Antigen Genes fromP. shigelloidesin a Recent Event,” Infection and Immunity, 2000, vol. 68, pp. 6056-6061.
Stroeher, Uwe H. et al., “A putative pathway for perosamine biosynthesis is the first function encoded with therfbregion ofVibrio choleraeO1,” Gene, 1995, vol. 166, pp. 33-42.
Van de Verg, Lillian et al., “Specific Immunoglobulin A-Secreting Cells in Peripheral Blood of Humans Following Oral Immunization with a BivalentSalmonella typhi-Shigella sonneiVaccine or Infection by PathogenicS. sonnei,” Infection and Immunity, 1990, vol. 58, pp. 2002-2004.
Viret, Jean-Francois et al., “Molecular cloning and characterization of the genetic determinants that express the completeShigellaserotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains,” Molecular Microbiology, 1993, vol. 7, pp. 239-252.
Wang, Lei et al., “Expression of the O antigen gene cluster is regulated by RfaH through the JUMPstart sequence,” FEMS Microbiology Letters, 1998, vol. 165, pp. 201-206.
Whitfield, Chris et al., “Structure, Assembly and Regulation of Expression of Capsules inEscherichia coli,” Molecular Microbiology, 1999, vol. 31, pp. 1307-1319.
Xu, D. et al., “Abstract B-436: Genetic and Functional Studies of theShigella sonneiRfb/Rfe Gene Clust
Cisar John O.
Kopecko Dennis J.
Xu De-Qi
Gangle Brian J
Minnifield Nita M
Swanson & Bratschun LLC
The United States of America as represented by the Department of
LandOfFree
Vaccine for protection against Shigella sonnei disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine for protection against Shigella sonnei disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine for protection against Shigella sonnei disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262767